Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Fibrolamellar hepatocellular carcinoma 1

Interventions

Nivolumab 3Ipilimumab 3poly ICLC 2Specimen Handling 2Sorafenib 2Irinotecan 2Cyclophosphamide 2spartalizumab 1sapanisertib 1pembrolizumab 1fludarabine 1durvalumab 1dostarlimab 1dehydroftorafur 1balstilimab 1atezolizumab 1aflibercept 1Whole-Body Irradiation 1Watchful Waiting 1Vincristine 1Tacrolimus 1Surveys and Questionnaires 1Sunitinib 1Prednisone 1Platinum 1Oxaliplatin 1Observation 1Mycophenolic Acid 1Mesna 1Leuprolide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fibrolamellar hepatocellular carcinoma × Leuprolide × Gastrointestinal × Clear all
NCT01642186 2022-12-29

Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
28 enrolled 13 charts
Gastrointestinal

Fibrolamellar hepatocellular carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡